Keyphrases
Histone Deacetylase Inhibitor (HDACi)
100%
Oncolytic Adenovirus
100%
Resistant Cells
57%
Belinostat
57%
Reolysin
42%
Histone Deacetylase 1 (HDAC1)
28%
T-cell Lymphoma
28%
Anti-lymphoma
28%
Reovirus
28%
Clinical Issues
14%
Molecular Mechanism
14%
Cross-resistance
14%
Effective Therapy
14%
Cell Death
14%
Drug Resistance
14%
Vulnerability
14%
In Vivo Model
14%
Lymphoma Cells
14%
Multidrug-resistant
14%
Decreased Expression
14%
Drug Class
14%
Cell Line Models
14%
Lymphoma Patients
14%
Acquired Resistance
14%
Acetylated Histone
14%
Novel Therapeutics
14%
Vorinostat
14%
Inhibitor Resistance
14%
Refractory Patients
14%
IRF1
14%
Panobinostat
14%
Romidepsin
14%
Clinical Formulation
14%
Medicine and Dentistry
Oncolytic Reovirus
100%
Pelareorep
42%
Reoviridae
28%
Clinical Formulation
14%
Pharmacology, Toxicology and Pharmaceutical Science